RESUMO
BACKGROUND: Cytokeratin 7 (CK7) and Cam 5.2 are often used to differentiate extramammary Paget's disease (EPD) from squamous cell carcinoma (SCC) in situ because they are generally considered to be expressed in the former but not in the latter. However, we have encountered CK7+ and Cam 5.2+ SCCs. METHODS: We evaluated CK7, Cam 5.2 and Ber-Ep4 expression in SCC and EPD. RESULTS: We found significant CK7 and Cam 5.2 positivity in SCCs, particularly in those with a pagetoid pattern. Only one case expressed Ber-Ep4. CONCLUSIONS: We conclude that CK7 and Cam 5.2 expression may occur in SCC. A panel including Ber-Ep4 is advisable for immunohistochemical differentiation of EPD from SCC.
Assuntos
Biomarcadores Tumorais/biossíntese , Carcinoma de Células Escamosas , Regulação da Expressão Gênica , Queratina-7/biossíntese , Queratinas/biossíntese , Proteínas de Neoplasias/biossíntese , Neoplasias Cutâneas , Biomarcadores , Carcinoma de Células Escamosas/metabolismo , Carcinoma de Células Escamosas/patologia , Feminino , Humanos , Masculino , Neoplasias Cutâneas/metabolismo , Neoplasias Cutâneas/patologiaAssuntos
Dermatopatias/patologia , Idoso , Axila , Elasticidade , Feminino , Humanos , Coxa da PernaAssuntos
Doenças Mamárias/patologia , Melanose/patologia , Mamilos/patologia , Complicações na Gravidez/patologia , Adulto , Biópsia , Feminino , Humanos , GravidezRESUMO
Infliximab infusion is not yet FDA-approved for psoriasis but has been reported to be very effective for plaque psoriasis. We report 2 patients without a history of psoriasis who after administration of infliximab for their inflammatory bowel disease experienced new onset, biopsy confirmed psoriasis.
